Publications by authors named "E M Whalen"
Congenital diaphragmatic hernia (CDH) is a complex congenital disorder often accompanied by long-term feeding difficulties. There is a paucity of published data regarding the impact of swallowing difficulties on long-term patient outcomes. Our study attempts to evaluate this phenomenon.
View Article and Find Full Text PDFRitlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma (JAK3/TEC) family kinase inhibitor approved for the treatment of severe alopecia areata (AA). Benefit-risk profiles of two doses of ritlecitinib (50 mg vs 30 mg once daily) were evaluated by integrating patient preferences and clinical efficacy and safety estimates for ritlecitinib. A discrete-choice experiment (DCE) was utilized to elicit preferences for benefit and safety attributes of systemic AA treatments.
View Article and Find Full Text PDFSoil microbes are a major source of organic residues that accumulate as soil organic matter, the largest terrestrial reservoir of carbon on Earth. As such, there is growing interest in determining the microbial traits that drive soil organic matter formation and stabilization; however, whether certain microbial traits consistently predict soil organic matter accumulation across different functional pools (e.g.
View Article and Find Full Text PDFArticle Synopsis
- Diverse genetic respiratory disorders can lead to severe pulmonary hypertension (PH) in newborns, but there are still many unresolved questions about the best ways to diagnose and manage these conditions for better long-term results.
- A multidisciplinary team of pediatric specialists has come together to tackle the current challenges in clinical approaches and support for families of infants with developmental lung disease (DEVLD).
- The review discusses the clinical features of infants with DEVLD/DEVLD-PH, highlights decision-making complexities such as genetic testing and imaging, and stresses the need for teamwork, communication, and comprehensive counseling for families.
Background: This post hoc, pooled analysis examined the relationship between different weight gain categories and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy.
Methods: Data were pooled from the control arms of three phase III clinical studies (NCT00596830, NCT00254891, and NCT00254904), and the maximum weight gain in the first 3 months from treatment initiation was categorised as >0%, >2.5%, and >5.